Skip to main content

Advertisement

Table 1 Details of the included studies

From: Work-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysis

Data sets Articles Conditions Active interventions Patients Work-related outcomes Study duration (in weeks) OQS score
1 Albert et al. 2013 [10] Chr. back pain Amoxicillin–Clavulanate 162 Time lost from work 52 5
2 Baron et al. 2010 [14] Chr. back pain Pregabalin 217 WPAI 5 4
3 Carlsson & Sjölund 2001 [19] Chr. back pain Acupuncture, electroacupuncture 51 Employment status 32 5
4 Jarzem et al. 2005 [25] Chr. back pain TENS 350 McGill Work Scale 12 5
5 Lehmann et al. 1986 [29] Chr. back pain TENS, electroacupuncture 54 Employment status 3 4
6 Licciardone et al. 2003 [30] Chr. back pain Osteopathic manipulative treatment 91 Time lost from work 20 3
7 Skljarevski et al. 2009 [34] Chr. back pain Duloxetine 404 BPI-I 13 5
8 Skljarevski et al. 2010a [35] Chr. back pain Duloxetine 236 BPI-I, WPAI 13 4
9 Skljarevski et al. 2010b [36] Chr. back pain Duloxetine 401 BPI-I, WPAI 12 3
10 He et al. 2005 [24] Chr. neck pain Body acupuncture + body electrostimulation + ear acupressure 24 Activity impairment at work 4 2
11 Manchikanti et al. 2010 [31] Chr. neck pain Bupivacaine and steroid injection 120 Employability, employment status 96 5
12 Bennett et al. 2003 + 2005 [16, 17] Fibromyalgia Tramadol-Acetaminophen 315 FIQ, time lost from work, SF-36 8 3
13 Bradley et al. 2010 [18] + Arnold et al. 2009 [12] (Arnold et al. 2005 [11] + Chappell et al. 2008 [20]) Fibromyalgia Duloxetine 1332 Bradley 2010 [18]: FIQ, Arnold 2009 [12]: SDS (Arnold 2005 [11]: BPI, Chappell 2008 [20]: SDS) 12-28 Review (Arnold et al. 2005 [11]: 5, Chappell et al. 2008 [20]: 3)
14 Straube et al. 2011 [4] Fibromyalgia Pregabalin 2757 FIQ, time lost from work, SF-36, SDS, MAF 8-14 Review
15 Chappell et al. 2009 [21] Osteoarthritis (knee) Duloxetine 231 BPI-I 13 5
16 Chappell et al. 2011 [22] Osteoarthritis (knee) Duloxetine 256 BPI-I 13 5
17 Markenson et al. 2005 [32] Osteoarthritis Oxycodone 109 BPI-I 12 4
18 Kavanaugh et al. 2006 [26] Psoriatic arthritis Infliximab 200 SF-36, employment status, employability, impact on productivity at work (VAS), time lost from work 22 3
19 Kavanaugh et al. 2013 [28] Psoriatic arthritis Golimumab 405 Impact on productivity at work (VAS) 24 4
20 Egsmose et al. 1997 [23] Reactive arthritis Sulphasalazine 83 Time lost from work 24 3
21 Bejarano et al. 2008 [15] Rheumatoid arthritis Adalimumab + MTX 148 Employment status, WIS, Time lost from work 56 5
22 Kavanaugh et al. 2009 [27] Rheumatoid arthritis Certolizumab pegol + MTX 1601 WPS, time lost from work 24 + 52 3
23 Meireles et al. 2010 [33] Rheumatoid arthritis Low-level laser therapy 82 DASH 8 5
24 Smolen et al. 2006 [37] Rheumatoid arthritis Infliximab + MTX 1004 Employability, time lost from work 54 5
25 Strand et al. 1999 [38] Rheumatoid arthritis Leflunomide, MTX 482 Productivity at work 48 4
26 Barkham et al. 2010 [13] Ankylosing spondylitis Entanercept 40 WIS, time lost from work 12 3
27 van der Heijde et al. 2006 [39] Ankylosing spondylitis Infliximab 279 SF-36, impact on productivity at work (VAS), time lost from work 24 4
  1. BPI-I – Brief Pain Inventory: Interference with normal work; chr. – chronic; DASH – Disabilities of the Arm, Shoulder and Hand Questionnaire; FIQ – Fibromyalgia Impact Questionnaire; MAF – Multidimensional Assessment of Fatigue; MTX – methotrexate; OQS – Oxford Quality Scale; SDS – Sheehan Disability Scale; SF-36 – Short Form 36 Health Survey; TENS – transcutaneous electrical nerve stimulation; VAS – visual analogue scale; WIS – Work Instability Scale; WPAI – Work Productivity and Activity Impairment Questionnaire; WPS – Work Productivity Survey. For reviews, information in brackets refers to the primary publications on which the reviews were based.